Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2017

View Archived Issues

EMA committee recommends orphan drug designation for MK-0677

GABA(A) positive allosteric modulator shows promise in irritable bowel syndrome model

Bioverativ to acquire True North Therapeutics and obtain worldwide rights to TNT-009

European Commission grants marketing authorization for Axumin

Pfizer gene therapy granted U.S. orphan designation for Duchenne muscular dystrophy

Ninlaro capsules become available in Japan for the treatment of multiple myeloma

Preliminary results show nearly 100% immune response rates in clinical study of Pennvax-GP

miRagen Therapeutics' MRG-106 named orphan medicinal product in E.U.

Liquidia Technologies reports positive results from phase I study of LIQ-865

RDX-8940, an improved GPBAR1 agonist for treating NAFLD/NASH

FDA committee recommends approval of Endari for sickle cell disease

FDA awards fast track designation to CM-4620 for acute pancreatitis

Radius Health reports topline results from Tymlos extension trial

FDA committee recommends approval of neratinib in HER2-positive breast cancer

HitGen forms drug discovery collaboration with Scripps Research Institute and Calibr

Aronora initiates phase I study of xisomab 3G3

EMA awards orphan drug designation to Actinium's Actimab-A

T-cell differentiation antigen CD6, a potential target for treating multiple sclerosis

ProtoKinetix gives update on its testing of retinal replacement therapy with AAGP

Aerie reports phase III topline results from MERCURY 2 study of Roclatan

Protagonist Therapeutics receives SBIR grant to develop biomarkers of IL-23R antagonist activity

FDA grants priority review to sBLA for Opdivo in previously treated HCC

Concert Pharmaceuticals shareholders approve CTP-656 asset purchase agreement with Vertex

Mundipharma launches Mundesine in Japan

Phase II study evaluates oral levosimendan in amyotrophic lateral sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...